scispace - formally typeset
X

Xinkang Wang

Researcher at Bristol-Myers Squibb

Publications -  16
Citations -  1165

Xinkang Wang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Venous thrombosis & Thrombus. The author has an hindex of 14, co-authored 16 publications receiving 1095 citations.

Papers
More filters
Journal ArticleDOI

Effects of factor IX or factor XI deficiency on ferric chloride‐induced carotid artery occlusion in mice

TL;DR: While FXI and FIX deficiencies were indistinguishable in the carotid artery injury model, there was a marked difference in a tail‐bleeding‐time assay, suggesting therapeutic inhibition of FXI may be a reasonable strategy for treating or preventing thrombus formation.
Journal ArticleDOI

An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research

TL;DR: This study provides a simple, sensitive and highly controlled method for limiting vessel injury in mice to better detect the efficacy of antithrombotic drugs and/or evaluate therapeutic targets.
Journal ArticleDOI

Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.

TL;DR: Enhanced clot lysis was demonstrated in FXI‐deficient mouse and human plasma compared to those supplemented with FXIa and therapeutic inhibition of FXI may be a reasonable therapeutic strategy to treat or prevent venous thrombosis.
Journal ArticleDOI

Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis.

TL;DR: The data suggest that the inhibition of MEK1/2 results in neuroprotection from reperfusion injury and that this protection may be associated with the reduction in apoptosis.
Journal ArticleDOI

Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.

TL;DR: Evidence is provided for a role of TAFIa in venous thrombosis in mice, and an optimized vena cava injury model appropriate for the evaluation of antithrombotic drugs and the characterization of novel therapeutic targets is described.